[Ip-health] US threatens to curb funding of Colombia peace process, if compulsory license on Novartis cancer drug patent is granted

PERFECT, Chase cperfect at coalitionplus.org
Tue May 10 07:45:33 PDT 2016


No shortage of irony that the US would threaten to prioritize its war on
generic drugs over its more famous "war on (recreational) drugs".
On May 10, 2016 9:57 AM, "Jamie Love" <james.love at keionline.org> wrote:

> This  is a story, from Colombia, about a letter by Senator Hatch staffer
> Everert Eissestat, delivered to Colombia government, threatening to end US
> funding of peace process, if Colombia grants compulsory license on Swiss
> company Novartis owned cancer drug.  The letter was reportedly delivered by
> the US embassy.
>
> ​There is also a video on the link, and English translation following the
> Spanish.
>
>
>
> http://noticiasunolaredindependiente.com/2016/05/09/noticias/ee-uu-amenaza-con-torpedear-ayuda-economica-para-posconflicto/
>
>
> ​EE.UU. amenaza con torpedear ayuda económica para posconflicto : Noticias
> UNO, La Red Independiente​
> ​May 9, 2016​
>
>
> ​El Ministerio de Salud recibió de la embajada de Estados Unidos una carta
> en la que se le advierte que si persiste en su decisión de liberar la
> patente de una droga suiza contra la leucemia, el país podría perder la
> financiación que el presidente Obama prometió para financiar el
> posconflicto.
>
> “Vemos con preocupación que este caso pueda crear un inconveniente en la
> aprobación de recursos de la iniciativa llamada Paz Colombia”, dice la
> misiva.
>
> La nota diplomática le traslada al Ministerio de Salud las observaciones
> que, luego de un anuncio suyo, vino a tramitar el jefe del Comité de
> Finanzas de Estados Unidos, Everert Eissestat, pues, según él, en caso de
> que Colombia libere la patente “estaría violando los derechos de propiedad
> intelectual de la empresa Novartis, así como el Tratado de Libre Comercio
> Colombia-Estados Unidos”.
>
> La molécula de la discordia se llama Imatinib y es el ingrediente activo
> del Glivec de Novartis, este bloquea la señal que estimula la producción
> anormal de glóbulos blancos, en enfermos de Leucemia, pero el tratamiento
> completo de un solo paciente cuesta 60 millones de pesos y por su venta
> entre 2008 y 2014, Novartis habría obtenido ingresos por 400 mil millones
> de pesos.
>
> Pero según la nota diplomática, si Colombia toma tal medida: “La industria
> farmacéutica de Estados Unidos y los grupos de interés relacionados podrían
> llegar a ser muy vocales (sic) e interferir con otros intereses que pudiera
> tener Colombia en Estados Unidos”.
>
> Everert Eissestat, que también ha sido subsecretario del Tesoro para
> América Latina y orienta la bancada republicana en asuntos de comercio
> exterior, admite en su carta que Novartis no es una empresa norteamericana,
> pero sostiene que un gesto hacia ella se podría interpretar como una
> amenaza para las farmacéuticas que sí están en su territorio.​
>
> ===========
>
> Google Translate version
>
> The Ministry of Health received from the US embassy a letter in which he
> warns that if he persists in his decision to release the patent from a
> Swiss drug against leukemia, the country could lose funding that President
> Obama promised to finance post-conflict.
>
> "We are concerned that this case may create a problem in resource approval
> of the initiative called Peace Colombia," says the letter.
>
> The diplomatic note he moved to the Ministry of Health observations, after
> an announcement of his, came to arrange the head of the Finance Committee
> US Everert Eissestat, because, according to him, if Colombia free patent
> "would violating intellectual property rights of Novartis, as well as the
> Free Trade Agreement Colombia-United States. "
>
> The molecule of contention is called Imatinib and is the active ingredient
> of Glivec Novartis, it blocks the signal that stimulates the production of
> abnormal white blood cells in patients with leukemia, but the full
> treatment of a single patient costs 60 million pesos for sale between 2008
> and 2014, Novartis would have earned revenues of 400 billion pesos.
>
> But according to the diplomatic note, if Colombia takes such as: "The
> pharmaceutical industry in the US and related interest groups could become
> very vocal (sic) and interfere with other interests that could have
> Colombia in the United States."
>
> Everert Eissestat, which has also been Treasury undersecretary for Latin
> America and orients the Republican caucus on foreign trade, admits in his
> letter that Novartis is not an American company, but maintains that a
> gesture towards it could be interpreted as a threat to pharmaceutical who
> are themselves in their territory.
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
>



More information about the Ip-health mailing list